Stock Price
6.29
Daily Change
-2.18%
Yearly
56.08%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Cochlear 185.48 3.42 1.88% -6.06%
CSL 257.22 7.79 3.12% -5.34%
Integral Diagnostics Ltd 4.00 -0.01 -0.13% -10.22%
Mesoblast Ltd 1.09 -0.04 -3.11% -53.02%
Mayne Pharma 0.25 -0.01 -3.92% -24.62%
Opthea Ltd 1.15 -0.03 -2.54% -41.18%
Paradigm Biopharmaceuticals Ltd 1.37 -0.03 -1.80% -40.65%
Pacific Edge 1.14 -0.03 -2.56% 7.55%
Polynovo Ltd 1.24 -0.03 -1.98% -52.50%
PYC Therapeutics Ltd 0.13 0.01 4.17% -10.71%
Ramsay Health Care 62.22 1.60 2.64% -1.19%
ResMed 31.15 -0.25 -0.80% 14.44%
Sonic Healthcare 37.75 0.56 1.51% 9.83%


Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Limited is a radiopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) to treat cancer. In MTR therapy, radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The Company's lead products include TLX250/TLX250-CDx for diagnosis and treatment of renal (kidney) cancer; TLX591/TLX591-CDx for diagnosis and treatment of metastatic castrate-resistant prostate cancer and TLX101 for the treatment of glioblastoma (brain cancer).The Company's pipeline include development and commercialization of several clinical-stage products that address unmet medical needs in oncology and rare diseases.